Botanix Pharmaceuticals Limited (ASX:BOT) Annual Report 2025



The latest annual report of Botanix Pharmaceuticals Limited (BOT) was published on 30 Jun 2025. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - BOT Annual Results

Amounts in AUD

Total Revenue
$5.76M
Gross Profit
$13.39M
EBIT
$-44.64M
Net Tangible Assets
$59.89M
Net Income
$-86.40M
Capital Expenditures
-

BOT Income Statement 2025 Annual Report

As per the latest Income Statement of BOT, the Net revenue increased by $5.16M (857%) compared to the previous period. The operating income in 2025 increased by - (-). The net income as per the annual report was $-86.40M which decreased by $-72.53M (-523%) compared to previous year.

Income Statement Report (2025/2024)

2025 2024
Total Revenue $5.76M $601.82K
Gross Profit $13.39M $13.39M
Operating Income - -
Income Before Tax - -
Net Income $-86.40M $-13.87M

Balance Sheet - BOT 2025 Annual Report

Read further: BOT Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Botanix Pharmaceuticals Limited showed the company increased the cash on balance sheet by $0.00 (0%). The Net tangible assets of BOT on the balance sheet were at $59.89M which is $0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2025/2024)

2025 2024
Cash $31.61M $31.61M
Total Assets - -
Long Term Debt - -
Total Liabilities $1.08M $1.08M
Total Shareholder Equity - -
Net Tangible Assets $59.89M $59.89M

Cash Flow Statement - BOT 2025 Annual Report

The 2025 annual cash flow statement of Botanix Pharmaceuticals Limited showed that the net income decreased by $-72.53M (-523%) compared to previous reporting period. Also the capital expenditure of BOT increased by - (-).

As of 2025, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2025/2024)

2025 2024
Net Income $-86.40M $-13.87M
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

Botanix Pharmaceuticals Limited Annual Report History

Income Statement

Income Statement history of Botanix Pharmaceuticals Limited (ASX:BOT)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2020
Total Revenue $5.76M $601.82K $0.00 $7.74M
Cost Of Revenue $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses $0.00 $0.00 $0.00 $0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit $0.00 $0.00 $0.00 $0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense $0.00 $0.00 $0.00 $0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income $-86.40M $-13.87M $-9.15M $-16.73M
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of Botanix Pharmaceuticals Limited (ASX:BOT)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2020
Cash $31.61M $31.61M - -
Total Assets - - - -
Total Liab $1.08M $1.08M - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets $59.89M $59.89M - -

Cash Flow Statement

Cash Flow Statement history of Botanix Pharmaceuticals Limited (ASX:BOT)

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2020
Net Income $-86.40M $-13.87M - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -